A groundbreaking study published in *Nature Communications* provides the first randomized, placebo-controlled evidence that semaglutide, a GLP-1 receptor agonist, can slow biological aging in adults with HIV. Conducted by researchers from the University of California San Diego, the study analyzed 108 participants suffering from HIV-associated lipohypertrophy, with half receiving semaglutide injections over 32 weeks. Results indicated that those treated with semaglutide exhibited a 9% reduction in biological aging markers, as measured by the DunedinPACE epigenetic clock, and showed significant improvements in health markers associated with aging. The drug's mechanisms may include reducing inflammation and metabolic stress, which are key contributors to accelerated aging in HIV patients. In a related pilot study, 42% of participants with metabolic dysfunction saw reduced biological aging rates. The findings suggest that GLP-1 therapies could have broader implications for aging management in the general population. Future studies are needed to confirm these results and explore the potential of combining GLP-1 therapy with lifestyle interventions.